56 of 57 inspected 503B facilities received a Form 483

Of the 57 facilities on the FDA's 503B register with an inspection date, 56 have a Form 483 recorded against that inspection and 1 does not.1 It is not a claim that 98.2% of compounders are dangerous. A Form 483 is the document an investigator leaves at the end of an inspection listing what they observed. On this register, leaving one is the normal ending.

38 of the 57 inspections on the register happened in the twelve months to October 22, 2026, and 37 of those produced a Form 483 — 97.4%, against 98.2% across the whole file.1 A finding rate that holds steady while the inspection count rises points to one standard applied to more facilities, not a crackdown.

A Form 483 is where an inspection ends, not where enforcement begins. The register's action column shows what happened next: 5 facilities have a warning letter recorded, 5 a regulatory meeting, 2 an FMD-145 letter and 2 an untitled letter.1 42 are recorded simply as open. So of 56 facilities with observations against them, 14 — 25.0% — have a further action on the file.2 For one of the 14, BayCare Central Pharmacy, the action on file is an FMD-145 letter from 2023, older than its 2026 inspection. That gap is why a single 483 should not be quoted as a finding of wrongdoing.

Inspections on the file run from April 2025 to September 2026, distributed as 2025: 28 and 2026: 29.1 The register carries one row per facility holding its most recent inspection, so an older inspection is overwritten rather than added. The median inspected facility was last seen 0.8 years ago. Any rate computed here is therefore a rate across current inspection records, not across every inspection the FDA has ever conducted.

Names link to the page for that record where one is published.

The numerator and the denominator come out of the same two columns of one file. From the FDA's outsourcing facility register we take every row with a "Last Inspection" date, which gives the denominator of 57; of those we count the rows where the register records a Form 483 issued.1 Facilities with no inspection date are excluded. They have their own page. Counting them here would measure inspection coverage, not findings.

A rate against the whole register would sound more alarming and say less, because it moves whenever the FDA inspects more facilities, whatever the inspections find.

The escalation counts are read from the register's own free-text action column, matched case-insensitively on the phrases the FDA uses there. A facility with no text in that column is not counted as escalated. Each facility counts once: where a warning letter close-out sits beside another action, the other action counts.1

1. A Form 483 records an investigator’s observations. It is not a final FDA determination and not an enforcement action.
2. The rate is the story, not any one facility.
3. The register covers all 503B facilities, not only those compounding a GLP-1.

For a program whose pharmacy you can look up here, start with our ranking of programs that name their pharmacy, or compare compounded semaglutide and compounded tirzepatide programs.